{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-042395","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.306000+00:00","generated_at":"2026-05-16T19:24:35.367412+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anteris reports positive 30-day DurAVR THV outcomes in 100 small-annuli patients","bullets":["No valve-related mortality and no moderate/severe paravalvular leak at 30 days.","Mean gradient 8.2 mmHg; effective orifice area 2.2 cm², reflecting single-digit gradients.","97% freedom from moderate/severe prosthesis-patient mismatch vs 11-35% in SMART Trial.","Technical success rate 100% in the last 50 consecutive patient implants."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-042395","json":"https://secwatch.observer/filing/0001140361-25-042395.json","markdown":"https://secwatch.observer/filing/0001140361-25-042395.md","text":"https://secwatch.observer/filing/0001140361-25-042395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125042395/0001140361-25-042395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125042395/ef20059387_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:24:35.367412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}